Saturday, July 23, 2016

BTIG starts Insulet, Intersect at neutral

BTIG starts Insulet, Intersect at neutral

July 13, 2016 by · Leave a Comment 

Tweet BTIG Research initiated research of Insulet (NASDAQ:PODD) and Intersect ENT (NASDAQ:XENT) with “neutral” ratings. Shares of Insulet closed at $32.21 and shares of Intersect at $13.51 on Tuesday. Analyst Sean Lavin writes that he sees Insulet’s core business as fairly valued at five times next 12 months revenue as both the major upside events […]

Antibe to have Phase 2 pain data by third quarter

Antibe to have Phase 2 pain data by third quarter

June 21, 2016 by · Leave a Comment 

Tweet Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) expects to have data by the third quarter this year from a small Phase 2 study of its naproxen derivative, ATB-346, in patients with osteoarthritis in the knee. “ATB-346 was designed to deliver non-addictive pain relief with significantly less gastrointestinal and cardiovascular damage than is typically associated with the use […]

Lipocine advancing pipeline, PDUFA for oral TRT

Lipocine advancing pipeline, PDUFA for oral TRT

May 31, 2016 by · Leave a Comment 

Tweet With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing towards Phase 3 ready status this year. “We have a robust pipeline with a number of key milestones in 2016 besides the decision on […]

Delivra implementing U.S. expansion strategy for topical creams

Delivra implementing U.S. expansion strategy for topical creams

May 24, 2016 by · Leave a Comment 

Tweet The major initiative for Delivra (TSX-V:DVA) in 2016 is to introduce its flagship LivRelief topical pain and nerve creams to the U.S. market, initially through a U.S. web store and Amazon, and then through regional and national retailers, such as Walmart, Walgreens and CVS. “We are launching an aggressive digital campaign shortly, and later […]

Rodman starts LabStyle Innovations at buy

Rodman starts LabStyle Innovations at buy

May 9, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday. LabStyle is an emerging digital health company focused on the monitoring and management of diabetes. Analyst Raghuram Selvaraju writes that the company has developed an integrated system to enable […]

HCW starts Strongbridge Biopharma at buy

HCW starts Strongbridge Biopharma at buy

April 27, 2016 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday. “Within the span of two years, Strongbridge has made material progress to strengthen its rare endocrine portfolio and had strategically planted its footing in a Cushing’s syndrome asset with comparatively […]

USPTO extends Oramed patent term

USPTO extends Oramed patent term

April 12, 2016 by · Leave a Comment 

Tweet The U.S. Patent and Trademark Office has issued a patent term adjustment (PTA) extending the patent term by 18 months for Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent titled, “Methods and Compositions for Oral Administration of Proteins.” Oramed had previously received an allowance on the patent. The PTA increases the patent term from the standard 20 years […]

Oramed gets Indian patent for oral administration of proteins

Oramed gets Indian patent for oral administration of proteins

March 29, 2016 by · Leave a Comment 

Tweet Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule, ORMD-0801. Having completed multiple Phase 2a trials, a Phase 2b trial […]

Revive readies key clinical studies in gout and kidney stones

Revive readies key clinical studies in gout and kidney stones

March 1, 2016 by · Leave a Comment 

Tweet Revive Therapeutics (TSX-V:RVV; OTCQB:RVVTF) hopes to begin a pivotal Phase 2b clinical trial in mid-year with its Bucillamine drug candidate for the treatment of acute gout flares. “We believe that the Phase 2b data in gout will be a partner-enabling study with a large pharmaceutical company,” CEO, Fabio Chianelli, says in an interview with […]

Transition Therapeutics reports TT401 trial results

Transition Therapeutics reports TT401 trial results

February 1, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog, with dual GLP-1 and glucagon agonist activity. TT401 development collaborator, Eli Lilly, performed the Phase 2 study, enrolling 420 Type 2 diabetes subjects […]

Next Page »

Email Newsletters with Constant Contact
Google+